IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.
IFM Therapeutics launched in 2015 in Cambridge, Massachusetts, based on seed funding from the Boston-based venture capital fund Atlas Venture.[1] The company's founding involved seven people, a mix of executives and university professors.[1] Series A financing was provided by Atlas, London-based Abingworth, and Swiss pharmaceutical company Novartis.[1]
The company was originally formed with a dual development path, focusing on both autoimmune diseases and cancer immunotherapy. However, in 2017, the entire development program devoted to enhancing the body's innate immune response to cancer was purchased by Bristol-Myers Squibb, which set up a new company from this purchase and recruited IFM's CEO, Gary Glick, to head the new company.[2]